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ABSTRACT 
 
 
Background: Pediatric patients with Inflammatory Bowel Disease (IBD) often receive a 
delayed diagnosis due to the presence of a variety of nonspecific gastrointestinal and 
extra-intestinal symptoms. As a result, patients are at an increased risk for growth and 
pubertal delays, as well as other developmental problems. Therefore, there is great need 
for the development of a noninvasive, inexpensive, reliable, and objective method of 
diagnosing and monitoring this disease.  Fecal biomarkers have the potential for meeting 
all of these requirements, and are thought to have increased value because they may 
better reflect the interaction between luminal bacteria and the mucosal immune system 
than serum biomarkers.  Antibodies in the serum that are directed against Saccharomyces 
cerevisiae (ASCA) have been identified in patients diagnosed with Crohn disease (CD).  
It has been suggested that the presence and levels of ASCA, as well as other serum 
antibodies, may be able to predict the severity, duration, complications, and response to 
treatments and therapies in patients with IBD.  Data from an unpublished study carried 
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out at the Center for Inflammatory Bowel Disease at Boston Children’s Hospital shows 
that fecal ASCA is detectable in the stool of patients with CD, and that ASCA levels 
change over time and in response to disease activity. Therefore, the goal of the present 
study is to further explore the relationship between fecal ASCA and disease activity in 
patients with CD and to discern if differences in ASCA immunoglobulin subtypes reflect 
disease activity in pediatric patients with CD.   
 
Methods: Stool from 21 patients with Crohn disease, which were tested to be positive for 
ASCA, were analyzed in this study.  Of the 21 patients, 13 were categorized as having 
active disease, while 8 were categorized as having inactive disease.  ASCA 
immunoglobulin (Ig) testing and fecal lactoferrin (FLA) testing were performed on these 
samples.  Marker values were compared between the active and inactive disease groups.   
 
Results: Wilcoxon rank-sum and t-tests were performed to determine the statistical 
significance of the differences between subjects with active and inactive disease.  Patients 
with active disease had higher total ASCA levels than those with inactive disease (mean 
OD 450/620 value = .990 vs. .302 for active and inactive subjects respectively), and the 
differences between the two averages was found to be statistically significant when 
analyzed using both tests (p-value of t-test = .01; p-value of Wilcoxon rank-sum test = 
.02).  We do not have enough evidence to conclude that IgA, IgE, or IgM levels are 
significantly different in patients with active CD compared to those with inactive CD.  
However, after performing a non-parametric Wilcoxon rank-sum test on the IgG levels in 
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the two groups, it was found that the difference between the two groups was indeed 
statistically significant (p-value of Wilcoxon test = .02). FLA levels were found to not be 
significantly different in the two groups.  However, when an outlier was removed, the 
active disease group did have significantly higher FLA levels (p-value of t-test = 0.04; p-
value of Wilcoxon rank-sum test =0.04).   
 
Conclusions: This study indicates that fecal ASCA and fecal ASCA Ig subtypes may 
have value as noninvasive biomarkers for monitoring disease activity in pediatric patients 
with Crohn disease.  Future studies should analyze a larger sample size to confirm these 
findings and should investigate the relationship of fecal ASCA levels to other disease 
parameters such as disease location, therapy, and surgical treatment.  
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INTRODUCTION 
 
 Inflammatory Bowel Disease (IBD) affects about one million Americans and 
approximately twenty percent of those affected are diagnosed during childhood (Rufo & 
Bousvaros, 2007).  Crohn disease (CD) and ulcerative colitis (UC) are the two major 
subtypes of IBD (MedlinePlus, 2011), and both disorders are characterized by chronic 
intestinal inflammation. Although the pathogenesis of IBD remains unclear, it is 
generally accepted that it results from an abnormal and accentuated mucosal immune 
response to microflora in patients who are genetically susceptible (Saeed & Kugathasan, 
2008).  Symptoms and treatment options for IBD are similar in adult and pediatric 
patients.  However, children are at an increased risk for extra-intestinal manifestations of 
the disease, including detrimental effects on linear growth and pubertal development 
(Kelsen & Baldassano, 2008).  Pediatric patients, who account for about a quarter of all 
IBD cases, are an important group to study because unlike adults, children have not yet 
been exposed to the many years of environmental exposures that can impact disease 
progression.  As such, further epidemiologic studies in children may provide us with a 
better overall understanding of the etiology of IBD (Saeed & Kugathasan, 2008).   
 
Clinical Presentation of Crohn Disease and Ulcerative Colitis 
The clinical presentation of IBD can greatly vary based on the disease location 
and degree of intestinal inflammation (Ruemmele et al., 1998).  While the two disorders 
have similar pathologic and clinical characteristics, they are also very distinct.  UC is 
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characterized by inflammation limited to the colonic mucosa, and this inflammation 
always begins in the rectum and extends proximally in a continuous fashion (Higuchi & 
Bousvaros, 2012).  In contrast, the inflammation observed in patients with CD can occur 
in any part of the gastrointestinal (GI) tract from the mouth to the perianal area, and is 
distinct from UC in that the inflammation is transmural in nature and often characterized 
by skip lesions (Crohn Disease, 2011; Higuchi & Bousvaros, 2012).    Due to the 
transmural nature of inflammation, patients with CD often present with fibrosis, 
strictures, and fistulas, which are features that are not generally observed in patients with 
UC (Higuchi & Bousvaros, 2012).    Patients with features of both UC and CD, including 
those presenting with very mild histologic inflammation in the end of the small intestine 
(terminal ileum), or those with colonic inflammation when there is a significant family 
history of CD, are generally classified as having indeterminate colitis (IC) (Bousvaros et 
al., 2007).  
CD and UC can be similar in clinical presentation, and both disorders can present 
with a number of intestinal and extra-intestinal symptoms (Higuchi & Bousvaros, 2012). 
Patients with UC typically present with lower abdominal cramping and diarrhea that 
contains gross blood and mucus.  The presence of visible blood in the stool results is 
more expedient referral for subspecialty testing and an earlier diagnosis.  In contrast, 
patients with CD often experience a delay in diagnosis due to more indolent symptoms, 
including weight loss or reduced growth velocity.  Symptoms reported in patients with 
CD often reflect disease location.  Those with primarily colonic disease may have 
symptoms that mimic UC, whereas patients with CD involving the stomach or duodenum 
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may experience postprandial pain and delayed gastric emptying (Hendrickson et al., 
2002).  Extra-intestinal manifestations of both UC and CD include fever, weight loss, 
delayed growth and sexual maturation, arthralgias, oral ulcers, ocular complications, 
hepatobiliary disease, renal disease, and osteopenia.  While there are some distinct 
features of each disease, the overlap of these symptoms can often make the 
discrimination between the two diseases difficult (Hendrickson et al., 2002).   
 
Incidence of Inflammatory Bowel Disease 
The frequency of IBD is increasing in both pediatric and adult patients, especially 
in Western countries (Kelsen & Baldassano, 2008; Canani et al., 2004; Saeed & 
Kugathasan, 2008; Benchimol et al., 2011). In the United States, the prevalence of IBD is 
estimated to be approximately 0.4%.  Given that the present population of the US is about 
320 million, current estimates suggest that there are about 1.4 million people with IBD in 
this country (Saeed & Kugathasan, 2008).  Up to 25% of these patients are diagnosed as 
children or adolescents (Benchimol et al., 2011).   
 
Etiology of Inflammatory Bowel Disease 
The etiology of IBD is attributed to a cryptic interplay between genetic, 
environmental, gut microbial, and immunologic influences, which has greatly hindered 
the development of clinical tests for use in screening and diagnosing patients with either 
UC or CD (Papa et al., 2012).  There is clearly a heritable component to IBD, and studies 
have shown that children diagnosed with either UC or CD are more likely to have a 
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presence of positive family history (Kelsen & Baldassano, 2008).  Nonetheless, direct 
correlates have been elusive to date.  Overall, twin studies have shown us that genetics 
can only account for up to 50% of susceptibility to CD, and an even lower contribution to 
UC.   Even in the context of monozygotic twins with identical genetic makeup, the 
concordance rate is only 16%-36% (Benchimol et al., 2011).  However, these findings 
have led to significant research efforts in identifying other triggers that must play a 
critical role in the etiology of IBD (Kelsen & Baldassano, 2008).   
Environmental risk factors such as smoking, diet and certain drugs have been 
implicated in the etiology of IBD (Saeed & Kugathasan, 2008).  Additionally, “Western 
life-style” has been suggested as another factor that could contribute to the development 
of the disease.  For example, the “cold chain hypothesis” proposes that there could be an 
increase in disease-inducing bacteria as a result of food refrigeration.  Furthermore, the 
“hygiene hypothesis” suggests that increased sanitation has resulted in an increased risk 
of IBD through a combination of diminished early exposure to infectious agents, 
including those related to farm animals.  This has resulted in a net suppression and 
ultimate dysregulation of what has become a highly evolved but largely underutilized 
immune system (Benchimol et al., 2008; Saeed & Kugathasan, 2008). 
In recent years there has been increased interest in the role played by commensal 
enteric microflora in the pathogenesis of IBD (Saeed & Kugathasan, 2008).  A 
combination of existing basic science data and clinical observations support the 
hypothesis that normal bacteria present in the gut are related to the development of IBD 
(Kelsen & Baldassano, 2008; Saeed & Kugathasan, 2008).  Rodent models for IBD have 
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demonstrated that commensal bacteria are necessary for the development of colitis 
(Saeed & Kugathasan, 2008; Hendrickson et al., 2002; Papa et al., 2012).  In support of 
this hypothesis, antibiotic treatment, as well as fecal diversion has proven useful in some 
patients with IBD with CD (Hendrickson et al., 2002).  IBD patients have also 
demonstrated an increased level of mucosal antibodies directed against enteric bacteria as 
well as distinctive changes in the composition of the gut microbiome (Hendrickson et al., 
2002; Papa et al., 2012).  Despite ongoing research efforts, the reason(s) behind the 
abnormal response to normal intestinal bacteria observed in patients with IBD has not yet 
been fully elucidated (Saeed & Kugathasan, 2008).   
 
Immunopathogenesis of Inflammatory Bowel Disease 
 Gut-associated lymphoid tissue (GALT) is a specialized regional component of 
the mucosal immune system and is the first to make contact with luminal and ingested 
bacteria (Montilla et al., 2004).  GALT is composed of organized lymphoid tissues such 
as Peyer’s Patches (PP) and mesenteric lymph nodes, as well as lymphocytes distributed 
diffusely throughout the lamina propria and epithelium of the intestinal tract (Forchielli & 
Walker, 2005).  These lymphocytes play an important role in the mucosal immune 
response to invading microorganisms, while simultaneously modulating immune 
activation to physiologically down-regulate inflammation and systemic immune 
activation (Takebayashi et al., 2011).   
 IBD is considered to result from an abnormal immune response of cells 
comprising the GALT to the normal intestinal microbiome in patients who are genetically 
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susceptible.  This may be explained, at least in part, by the mucosal over-abundance of 
pro-inflammatory cytokines relative to down-regulatory cytokines.  Existing studies are 
further elucidating the roles played by regulatory T-cells and mucosal antigen presenting 
cells (APCs) in the development on this inflammatory milieu (Blumberg & Snapper, 
2009).    In addition, environmental factors such as smoking might influence this 
response (Blumberg & Snapper, 2009).   
 The genetic risk factors driving the development of IBD are still not fully 
understood.  However, it is predicted that these factors may result in modifications in 
intestinal epithelial cell barrier function and thereby luminal exposure to components of 
the innate and adaptive immune systems (Blumberg & Snapper, 2009).  It is also possible 
that genetic factors could directly contribute to changes in the composition of the 
intestinal microflora (Blumberg & Snapper, 2009).     
 
Importance of Diagnosing Crohn Disease versus Ulcerative Colitis 
The ability to differentiate CD from UC, as well as excluding other illnesses, is 
especially important in pediatric patients because of their inherent vulnerability to growth 
failure and delayed onset of puberty (Higuchi & Bousvaros, 2012).  In addition, earlier 
distinction between CD and UC improves the ability of clinicians to make decisions 
about treatment options, provide anticipatory guidance, facilitate discussions with the 
family, determine eligibility for clinical trials, and improve the focus and conduct of 
epidemiologic research (Higuchi & Bousvaros, 2012).  As the incidence of IBD rises, the 
importance of considering this diagnosis is increasing in patients presenting with 
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nonspecific intestinal symptoms or extra-intestinal manifestations (Canani et al., 2004).  
Retrospective epidemiologic studies show that there is a median delay of five months 
between the onset of symptoms and a diagnosis of IBD, and up to 25% of children suffer 
symptoms for greater than one year before receiving a diagnosis (Canani et al., 2004).  
This delay in diagnosis can result in delayed puberty, short stature, decreased bone 
density, and nutritional deficiencies, thereby increasing the morbidity of IBD (Canani et 
al., 2004).  As a result, the premium on early diagnosis is much higher in children and 
adolescents than it is in adult patients (Kelsen & Baldassano, 2008).   
The diagnosis of CD and UC is dependent on endoscopic examination, mucosal 
biopsy, and relevant imaging studies (Higuchi & Bousvaros, 2012).  These tests can be 
invasive, expensive, and may entail general anesthesia in pediatric patients, thus making 
them less attractive for repeat interval assessments (Canani et al, 2006).  Therefore, there 
is a need to develop cost-effective and noninvasive techniques to diagnose and evaluate 
IBD, especially for use in pediatric practice (Canani et al., 2006).   
 
Serologic and Fecal Biomarkers 
Diagnostic methods to evaluate patients with IBD are invasive, uncomfortable, 
costly, and time consuming (Assche, 2011).  Furthermore, methods of monitoring disease 
activity through the use of clinical disease activity indices rely on data that is often 
colored by subjective impressions from the point of view of either the patient or clinician 
(Assche, 2011).  Although the endoscopic appearance of the intestinal mucosa is one way 
of assessing the degree of inflammation, a more feasible method of monitoring disease 
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activity is necessary so that clinical decisions can be made in the context of the most 
relevant data (Turner et al., 2010).  As a result, much research has been focused on the 
value of serologic and fecal biomarkers, which unlike previous endoscopic or clinical 
metrics are non-invasive and not reliant upon subjective monitoring techniques.  In the 
past fifteen to twenty years, serologic markers such as C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), albumin, and hemoglobin have been studied for 
use as biomarkers in assessing inflammation in patients with IBD (Assche, 2011; Turner 
et al., 2010).  However, these systemic biomarkers have limitations.  ESR and CRP levels 
reflect inflammation in the body, but they cannot be used to localize disease to any body 
part or organ system.  Due to such limitations, there is increasing interest toward 
developing region specific markers that can be used to more specifically assess 
inflammation in the intestinal tract (Assche, 2011).   
 Fecal biomarker testing may fulfill this requirement as it measures the levels of 
proteins derived directly from either the intestinal mucosa or associated immune response 
(Assche, 2011).  Furthermore, collecting and analyzing stool is noninvasive and 
inexpensive, thereby making serial measurement feasible.  The major drawback related to 
the use of fecal biomarkers is that they do not discriminate patients with IBD from those 
with acute infectious gastrointestinal disorders.  More research is needed to clarify the 
best clinical value of these biomarkers (Assche, 2011).  
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Fecal Lactoferrin 
 Fecal lactoferrin (FLA) is a widely studied noninvasive biomarker.  It is an iron-
binding protein that is secreted from epithelial cells and is released from activated 
neutrophils during degranulation (Pfefferkorn et al., 2010).  Elevated FLA levels 
differentiate patients with IBD from those with irritable bowel syndrome (Abraham & 
Kane, 2012; Pfefferkorn et al., 2010).  Increased FLA levels correlate with active disease 
in patients with both UC and CD (Pfefferkorn et al., 2010).  As such, FLA may be 
valuable in monitoring disease outcomes such as response to therapy or predicting 
disease relapse, and studies demonstrating that FLA correlates with mucosal healing and 
improved pathology support this claim (Abraham & Kane, 2012).   
 
ASCA 
Antibodies in the serum that are directed against Saccharomyces cerevisiae 
(ASCA) have been identified in between 40-80% of patients diagnosed with CD and are 
generally not found in those with UC (Higuchi & Bousvaros, 2012).  It has been 
suggested that the presence and levels of ASCA, as well as other serum antibodies, may 
be able to predict the severity, duration, complications, and response to treatments and 
therapies in patients with IBD (Prideaux et al., 2011).  As a result, there is much ongoing 
research evaluating the role of these serum antibodies in the diagnosis and assessment of 
children and adults with UC and CD.   
 The outcomes of studies evaluating the use of serum ASCA to diagnose CD and 
to differentiate CD from UC have varied considerably.  A large review of 204 previous 
 10 
studies concluded that serological antibodies, including ASCA, are not as valuable for the 
initial diagnosis of IBD, but may have a more significant role in helping clinicians 
discriminate between CD and UC (Table 1) (Prideaux et al., 2011).  However, this review 
also finds that there is considerable variability in serological responses in CD and UC, 
making it difficult to establish its use as a diagnostic tool.   
 
Table 1: Crohn Disease and Colonic Crohn Disease vs. Ulcerative Colitis – The data 
shows that ASCA has the best sensitivity and specificity for CD, and also shows that the 
presence of ASCA and the absence of pANCA, which is predictive of UC, are useful for 
differentiating CD from UC.  Taken from Prideaux et al., 2011.   
 
 
 
Rather than rely on single metrics, a strategy of combining multiple non-invasive 
serologic markers may be more useful in evaluating patients with known or suspected 
IBD.  To that end, Canani et al. (2006) concluded that if a combination of noninvasive 
tests (including ASCA levels) all had positive results, the probability that the patient had 
IBD was over 99%.  However, there would still be a need for radiological and endoscopic 
tests, as well as biopsies, to further classify the type of IBD.  A study using a Brazilian 
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cohort came to a similar conclusion, and they found that the low sensitivity of serum 
ASCA made it less attractive for use as a screen tool, but its relatively high specificity 
made it more useful for differentiating patients with CD from those with UC (Nisihara et 
al., 2009).  Canani (2004) further demonstrated that the combination of serum IgA and 
IgG ASCA positivity was highly specific for CD.  A total of 58.8% of patients with CD 
were IgA or IgG positive while only 10.6% of patients with UC, 7.8% of patients with 
IC, and 3.5% of controls had positive titers of ASCA IgA or IgG.  As shown in Figure 1, 
there was an increasing IgA and IgG ASCA titer pattern that correlated with increased 
disease activity as defined by the Pediatric Crohn Disease Activity Index (PCDAI).  
Mainardi et al. (2007) concluded that there is a need for more research to determine the 
diagnostic ability of serological ASCA, but that it may help distinguish between different 
forms of IBD.   
 
Figure 1:   Effect of Disease Activity (based on PCDAI Score) on ASCA IgA and IgG 
levels in pediatric patients with Crohn Disease – The figure demonstrates that there 
was a statistically significant (p<0.001) difference in ASCA IgA and IgG subtypes in 
patients with a PCDAI over 30 compares with those with a PCDAI of 10 and under. 
Taken from Canani et al., 2004. 
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Whereas elevated serum titers of ASCA are specific for CD, elevated serum titers 
of anti-neutrophil cytoplasmic antibodies (ANCA) have been shown to be more specific 
for patients with UC (Gupta et al., 2004).  Therefore, testing combining the two metrics is 
more accurate in discriminating between CD and UC.  Mainardi et al. (2007) 
demonstrated that the association ASCA+/ANCA- is 86% sensitive, 93% specific for CD 
with a positive predictive value of 75%.  On the other hand, ASCA-/ANCA+ was shown 
to be 70% sensitive, 86% specific for UC with a positive predictive value of 82% 
(Mainardi et al., 2007).   
 There is an abundance of research on the diagnostic value of serologic ASCA.  
However, few studies have investigated the value of fecal ASCA in diagnosing Crohn 
disease (Tang et al., 2012).  Nonetheless, recent studies have demonstrated that ASCA 
can be detected in stool of patients with IBD and can be used to differentiate between 
patients with CD and those without CD (Tang et al., 2012).  Fecal ASCA levels appeared 
to be significantly higher within six months of diagnosis and correlated with disease 
activity in patients with CD in comparison to those without CD.  As such, fecal ASCA 
may be a superior diagnostic tool than serum ASCA for differentiating between CD and 
other types of IBD.  It is possible that fecal antibodies better reflect the interaction 
between luminal bacteria and the mucosal immune system than serum antibodies (Tang et 
al., 2012).   
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SPECIFIC AIMS 
 
 Existing data suggest that measurement of serum ASCA is less useful in assisting 
clinicians in making an initial diagnosis of IBD than it is in differentiating patients with 
CD from those with UC.  However, little research has been done on the value of fecal 
ASCA in diagnosing IBD and more specifically, CD.  As suggested by Tang et al., 
(2012), the interaction between luminal bacteria in the GI tract and mucosal immunity 
may be better reflected by fecal ASCA.  Furthermore, analysis of ASCA Ig subtypes may 
also provide additional information with respect to mucosal disease activity.  Previous 
studies performed by our group in the Center for Inflammatory Bowel Disease at Boston 
Children’s Hospital have shown that not only is fecal ASCA detectable in the stool of 
patients with CD, but also that ASCA levels change over time and in response to disease 
activity.  Given that fecal ASCA levels appear to be more dynamic than serum ASCA 
levels, we hypothesize that fecal ASCA levels may reflect disease activity in patients 
with CD.  Therefore, the goal of the present study is to further explore the relationship 
between fecal ASCA and disease activity in patients with CD and to discern if differences 
in ASCA immunoglobulin subtypes reflect disease activity in pediatric patients with CD.  
More specifically, we will evaluate:  
1. The relationship between total fecal ASCA levels and disease activity  
2. The relationship between fecal ASCA Ig subtypes (IgA, IgG, IgM, IgE) and 
disease activity 
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3. The correlation between fecal lactoferrin (FLA) and ASCA levels in this patient 
population 
4. The relationship between other established serologic biomarkers, including 
albumin, and disease activity 
 
The aim of this study is to further investigate the utility of measuring fecal ASCA levels, 
as well as ASCA Ig subtypes, as novel noninvasive biomarkers for use in the assessment 
of disease activity in pediatric patients with Crohn disease. 
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METHODS 
 
Study Population 
Pediatric patients (age less than 18 years) with known or suspected IBD were 
recruited for this study from the Gastroenterology Program at Boston Children’s 
Hospital.  CD and UC were defined using standard endoscopic, radiologic, and histologic 
criteria.  We did not recruit patients with indeterminate colitis.  Patients with HIV, 
hepatitis B, or hepatitis C were excluded.  Additionally, those who refused to provide a 
stool sample or those with constipation who had used a suppository or enema in the past 
three days were excluded.  In addition to the patients with IBD, patients with constipation 
were recruited as controls for this study.   
 
Recruitment Methods 
The study protocol was reviewed and approved by the Boston Children's Hospital 
Committee on Clinical Investigation.  Subjects were identified for recruitment using 
Cerner Powerchart®, the electronic charting system used by the clinical programs at 
Boston Children’s Hospital.  These subjects were then approached during regularly 
scheduled outpatient or inpatient visits in the ambulatory clinics of the Center for 
Inflammatory Bowel Disease, the Gastroenterology inpatient floor, the Center for 
Ambulatory Infusions, and the Gastroenterology Procedure Unit.  Study personnel 
explained the details of the study and what participation would entail to patients and their 
parents. After sufficient time was given to answer questions, and patients expressed an 
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interest in participating, informed consent and assent were obtained.  After informed 
consent was obtained, subjects were assigned a study identification number, which 
maintained anonymity.   
 
Sample Collection and Processing 
Patients were asked to provide a paired blood and stool sample.  These samples 
were collected as close in time as possible to each other, and at a maximum of two weeks 
apart, in order to allow for accurate comparison of fecal and serum ASCA levels at a 
given point in time.  Serum was collected only if clinical labs were scheduled at the time 
of the outpatient or inpatient visit.  During outpatient clinic visits, subjects were provided 
a stool collection kit and were given the option of mailing in the sample via United States 
Postal Service, or bringing in the sample to the next clinic appointment. For those 
admitted to the inpatient service, stool and serum samples were collected by nursing staff 
during their hospitalization.   
Blood and stool samples were taken to the Clinical and Translational Study Unit 
(CTSU) at Boston Children's Hospital, where they were processed.  The blood samples 
were spun down, and the serum was saved and divided into 2-milliliter (mL) aliquots. 
Stool samples were similarly divided into 2mL aliquots.  All samples were labeled and 
stored in an -80 degree Celsius freezer until they were batched and shipped out for 
testing.  One aliquot of each sample was shipped out, and the rest were stored in the -80 
degree Celsius freezer for use in the event that samples were misplaced or needed to be 
retested for this study.  
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Sample Testing 
Batched serum and stool samples were shipped to TechLab Inc.® who sponsored 
this study.   TechLab Inc.® personnel were blinded to diagnoses, disease activity, and the 
dates that samples were collected.  TechLab Inc.® performed both quantitative and 
qualitative FLA tests (IBD-SCAN™ and IBD-CHEK™) on the stool samples, and 
performed the qualitative ASCA test (ASCA-CHEK™) on the stool and serum samples.  
IBD-SCAN™, a test developed by TechLab Inc.®, quantifies FLA in micrograms/ 
milliliter (µg/mL). ASCA-CHEK™ uses an anti-human immunoglobulin antibody 
conjugated to HRP and microwells coated with Saccharomyces cerevisiae antigens.  
Fecal specimens were diluted 1:20 in the kit diluent and results were determined by 
measurement of the optical density (OD) at 450nm/620nm on a dual wavelength 
spectrophotometer.  A reading of greater than or equal to.110 was defined as a positive 
result for stool samples, while a reading of greater than or equal to .080 was defined as a 
positive result for serum samples (TechLab®, 2008).  Additionally, TechLab Inc.® 
determined the discrete fecal IgG, IgA, IgE, and IgM levels using the same 
Saccharomyces cerevisiae coated plates used for ASCA-CHEK™.  The conjugates are 
specific for the different subtypes. For IgM and IgG a 2 step ELISA procedure was used, 
and for IgA and IgE a 3 step procedure was used. The results were again read at a dual 
OD (450/620nm) (R. Albert, personal communication, February 27, 2013). 
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Case Report Forms 
Case Report Forms (CRF) were prepared to facilitate standardized collection of 
all study data.  Data entered into the CRF was collected from Boston Children’s 
Hospital’s electronic charting system, Cerner Powerchart®.  A CRF was filled out for 
each subject that provided informed consent and provided a stool or blood sample.  
Examples of data that were collected included (Figures 2 and 3): date of diagnosis, 
disease activity, clinical lab results, ASCA and FLA results, and endoscopic test results.  
Patients were determined to have active disease if one or more of the following criteria 
were met:  
1. the need for increasing the dose of existing medications,  
2. the need for adding new medications to control symptoms,  
3. the need for new testing to diagnose symptoms. 
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Figure 2: Disease Information Section of the Case Report Form – Section D - the 
disease information component of the CRF - gives details about the subject’s diagnosis, 
disease activity at the time of the visit, and surgical history. 
 
 
 
 
SECTION D: DISEASE INFORMATION 
D1. Diagnosis:  CD……………………….1 
    UC……………………….2 
   Constipation……….3 
D2. Date of Onset of Symptoms:  __ __ /__ __ /__ __ __ __ 
D3. Date of Diagnosis:                    __ __ /__ __ /__ __ __ __ 
D4. Activity:   Active……… 1 
(If 2, Skip to D6)  Inactive…… 2 
D5. Reason (if active): Increase dose of existing medications…………..1 
    Add new medications to control symptoms…..2 
    New testing to diagnose symptoms……………….3 
    Missing...…………………………………………………………-9 
D6. Surgical Treatment:  Yes………..1 
(If 2, skip to E1)   No………….0 
D6a. Date:  __ __ /__ __ /__ __ __ __ 
D6b. Type:  Ileocecal Resection…………………………………..1 
   Stricturplasty……………………………………………..2 
   Right Hemicolectomy………………………………..3 
   Left Hemicolectomy………………………………....4 
   Colectomy and ileoanal pull through…………5 
Other (specify_______________)…………..........6 
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SECTION K: BASELINE BLOOD WORK 
CBC  
K1. WBC   _ _ . _ _  K cells/uL 
K2. HCT      _ _ _ . _ mg/dL 
K3. PLT          _ _ _ _ mg/dL 
K4. Neutrophils                      _ _ % 
K5. Lymphs                      _ _ % 
K6. Eos                      _ _ % 
K7. Monos                      _ _ % 
  
Chemistry  
K8.   Albumin                _ . _ g/dL 
K9.   SED Rate               _ _ mm/hr 
K10. ASCA            _ _ . _ eu/mL 
K11. ANCA         _ _ _ . _ eu/mL 
K12. Amylase               _ _ _ unit/L 
K13. ALT                 _ _ unit/L 
K14. Bilirubin (Tot)               _ . _ mg/dL 
K15. Alkaline 
        Phosphatase 
              _ _ _ unit/L 
K16. CRP           _ . _ _ mg/dL 
SECTION K: BASELINE LABS GENERAL INFORMATION 
K1. Date Serum Labs Completed          __ __/__ __/__ __ __ __ 
K2. Date Fecal Labs Completed       __ __/__ __/__ __ __ __ 
K3. Baseline Labs Form Completed:     __ __/__ __/__ __ __ __ 
K4. Staff Initials:    __ __ __ 
 
SECTION E: SPECIMEN COLLECTION 
E1. Serum Sample:  Date __ __/__ __/__ __  
E2. Fecal Sample:    Date __ __/__ __/__ __  
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Figure 3: Specimen and Lab Data in the Case Report Form – Sections E, K, M and N 
of the CRF record the dates that specimens were collected, the dates that lab testing was 
completed, the clinical lab results, and the research lab results completed by TechLab 
Inc.®.  
 
 
 
 
 
SECTION M: BASELINE LEVELS 
  
M1. IBD- CHEK™ Fecal Lactoferrin 
       (OD450/620) 
_ . _ _ _  
M2. IBD- CHEK™ Interpretation Positive………….1 
Negative………..0 
M3. IBD-SCAN™ Fecal Lactoferrin 
       (µg/mL) 
_ _ _ . _ µg/mL 
M4. IBD-SCAN™ Interpretation Positive………….1 
Negative………..0 
M5. Fecal ASCA-CHEK™ (OD450/620) _ . _ _ _ 
M6. Fecal ASCA-CHEK™ Titer _ _ _ _ 
M7. Fecal ASCA-CHEK™ Interpretation Positive………….1 
Negative………..0 
M8. Serum ASCA-CHEK™ (OD450/620) _ . _ _ _  
M9. Serum ASCA-CHEK™ Titer _ _ _ _  
 M10. Serum ASCA-CHEK™ Interpretation Positive………….1 
Negative………..0 
SECTION N: BASELINE ASCA IMMUNOGLOBULIN TYPES (ELISA) 
 Fecal Serum 
N1. IgA _ ._ _ _ OD 450nm _ ._ _ _ OD 450nm 
N2. IgG _ ._ _ _ OD 450nm _ ._ _ _ OD 450nm 
N3. IgE _ ._ _ _ OD 450nm _ ._ _ _ OD 450nm 
N4. IgM _ ._ _ _ OD 450nm _ ._ _ _ OD 450nm 
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Statistical Analysis 
For the purposes of this study, we analyzed data collected from patients with 
Crohn disease who had positive ASCA titers.  Data from patients with active disease 
were compared to those with inactive disease.  Total ASCA, as well as composite ASCA 
Ig subtypes, FLA, and albumin levels were compared between the active and inactive 
groups.  For each of these measures the mean, standard deviation, median, and 
interquartile range were calculated.  Relevant parametric (t-test) and non-parametric 
(Wilcoxon rank-sum test) testing was performed to determine the statistical significance 
of the differences between the two groups. 
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RESULTS 
 
Patient Population 
A total of 198 patients with a diagnosis of CD, UC, or constipation provided 
informed consent to participate in this study.  For the purposes of analyzing Ig subtype 
levels, only subjects with a positive fecal ASCA titer were considered.  Sixty-seven 
subjects provided fecal samples that had elevated ASCA titers, 24 of which were 
analyzed for Ig subtypes.  Of the 24 samples that were analyzed, 2 (8%) were samples 
from subjects diagnosed with UC, and 1 (4%) was from a control subject with 
constipation.  The data from these subjects was not analyzed due to the low sample size.  
The remaining 21 (88%) samples were those from subjects diagnosed with CD.  These 21 
subjects were then categorized as having active or inactive disease based on the criteria 
previously defined. More than 50% of the patients (n=13) were classified as having active 
disease, while 8 patients were classified as having inactive disease.   
 
Effect of Disease Activity on Fecal ASCA Levels 
 Mean ASCA-CHEK™ levels, as well as mean ASCA immunoglobulin subtype 
levels, are reported in Figure 4.   
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Figure 4: Mean Fecal ASCA Total and Subtype Levels in Patients with Inactive and 
Active Crohn Disease – Top of bar represents mean optical density value which 
represents ASCA or Ig subtype level, ± 95% confidence interval. 
 
 
Effect on Total Fecal ASCA (ASCA-CHEK™) 
  Wilcoxon rank-sum and t-tests were performed to determine the statistical 
significance of the differences in total fecal ASCA levels (as measured using the ASCA-
CHEK™ test) between subjects with active and inactive disease.  Patients with active 
disease had higher total ASCA levels than those with inactive disease, and the differences 
between the two averages was found to be statistically significant when analyzed using 
both tests.  Statistical data comparing these two groups are shown in Table 2.   
 
 
0.99 
1.13 
0.13 
0.57 
0.64 
0.30 
0.80 
0.14 
0.02 0.00 
0
0.5
1
1.5
2
2.5
Total (ASCA
CHEK)
IgA IgE IgM IgGFe
ca
l 
A
S
C
A
  L
e
ve
ls
 (
d
u
a
l 
O
D
) 
ASCA-CHEK™ and ASCA Ig Subtypes 
Active
Inactive
 25 
Table 2: Total Fecal ASCA levels (ASCA-CHEK™) In Patients with Crohn Disease 
- The sample size, mean, standard deviation, median, interquartile ranges, as well as the 
p-values for both statistical tests are shown.  The difference in total ASCA levels between 
patients with active and inactive CD is shown to be statistically significant when 
analyzed parametrically (t-test) and non-parametrically (Wilcoxon rank-sum test). 
*p<.05, active versus inactive Crohn Disease 
 
 
Figure 5 below, visually represents this statistically significant difference in total 
ASCA levels between the two groups using box and whisker plots.   
Figure 5: Total Fecal ASCA levels (ASCA-CHEK™) in Patients with Inactive and 
Active Crohn Disease – Box and whisker plots help visualize the dispersion and skew of 
that data and also identify outliers. 
 
Disease 
Activity 
N Mean±SD 
(OD450/620) 
Pt-test  Median (Q1, Q3) 
(OD450/620) 
PWilcoxon 
   0.01*   0.02* 
Inactive  8 0.302±0.209   0.288 (0.217, 0.330)  
Active  13 0.990±0.813   0.576 (0.433, 1.604)  
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Box and whisker plots allow for interpretation of the dispersion and skew of the data, and 
clearly identify the outliers.  In each plot, the box represents the interquartile range 
(IQR). The bottom of the box represents quartile 1, the top of box represents quartile 3, 
and the median is shown by the horizontal line within the box.  Each whisker extends to 
as much as 1.5 times the IQR and data beyond this are represented by points.  The mean 
is identified with a diamond-shaped point.   
 
Effect on Fecal ASCA Immunoglobulin Subtypes 
The t-test and Wilcoxon rank-sum test were also performed to compare levels of 
each immunoglobulin subtype (IgA, IgE, IgM and IgG) between patients with active and 
inactive disease.  The statistical data is shown in Table 3.  In Figures 6-9 box and whisker 
plots are used to report the data.   
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Table 3: Fecal ASCA Antibody Subtypes (IgA, IgE, IgM, IgG) in Patients with 
Crohn Disease – The table highlights the statistical difference between the two groups of 
subjects.  The sample size, mean, standard deviation, median, interquartile ranges, as well 
as the p-values for both statistical tests are reported for each fecal antibody subtype.  
*p<.05, active versus inactive Crohn disease. 
 
Fecal 
ASCA 
Subtype 
Disease 
Activity 
N 
Mean±SD 
(OD450/620) 
Pt-test 
Median (Q1, Q3) 
(OD450/620) 
PWilcoxon 
IgA 
Inactive 7 
 
0.797±0.627 
0.55 
0.532 (0.220, 1.454) 
0.81 
Active 1
3 
1.128±1.336 
 
0.499 (0.120, 1.279) 
 
IgE 
Inactive 7 
 
0.141±0.081 
0.83 
0.133 (0.074, 0.194) 
0.39 
Active 1
3 
0.130±0.114 
 
0.102 (0.052, 0.140) 
 
IgM 
Inactive 6 
 
0.024±0.033 
0.11 
0.003 (0.002, 0.065) 
0.19 
Active 1
3 
0.057±1.144 
 
0.068 (0.003, 0.437) 
 
IgG 
Inactive  6 
 
0.004±0.004 
0.07 
0.002 (0.002, 0.003) 
0.02* 
Active 1
3 
0.641±1.150 
 
0.126 (0.004, 0.521) 
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Figure 6:  IgA OD450/620 Readings in Patients with Inactive and Active Crohn 
Disease – A box and whisker plot of the optical densities of IgA levels in the two groups 
of patients is shown.  This representation illustrates the similarity in the median and 
interquartile ranges of the two groups.  The plot also clearly demonstrates the presence of 
two outliers in the active disease group that cause the mean IgA level for this group to be 
higher (mean IgA level of inactive group = 0.797; mean IgA level of active group = 
1.128). 
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Figure 7:  IgE OD450/620 Readings in Patients with Inactive and Active Crohn 
Disease - A box and whisker plot of the optical densities of IgE levels in the two groups 
of patients is shown.  This representation illustrates the similarity in the median and the 
mean of the two groups (also see Table 3).  The plot also clearly demonstrates the 
presence of two outliers.  
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Figure 8:  IgM OD450/620 Readings in Patients with Inactive and Active Crohn 
Disease - A box and whisker plot of the optical densities of IgM levels in the two groups 
of patients is shown.  The plot clearly demonstrates the presence of two outliers. The 
difference between the means of the two groups is not statistically significant when tested 
parametrically and non-parametrically. 
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Figure 9:  IgG OD450/620 Readings in Patients with Inactive and Active Crohn 
Disease - A box and whisker plot of the optical densities of IgG levels in the two groups 
of patients is shown.  This representation illustrates the differences in the medians and the 
means of the two groups.  A parametric test to assess the significance of the difference in 
the means (t-test) does not demonstrate a statistically significant difference (p=.07), 
however a non-parametric test (Wilcoxon rank-sum test) does demonstrate a statistically 
significant difference (p=.02).  In this case, a non-parametric test is a better measure of 
statistical significance due to the limitations of a small sample size.  The plot also clearly 
demonstrates the presence of two outliers in the active disease group.  
 
 
 
There is variation in immunoglobulin subtype OD450/620 readings between 
patients with active versus inactive CD.  Due to the measurement variability, in 
conjunction with a relatively small sample size, we do not have enough evidence to 
conclude that IgA, IgE, or IgM levels are significantly different in patients with active 
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CD compared to those with inactive CD.  On the other hand, after performing a non-
parametric Wilcoxon rank-sum test on the IgG levels in the two groups, it was found that 
the difference between the two groups was indeed statistically significant (p-value of 
Wilcoxon test = .02).  A Wilcoxon rank-sum test is used to compare two related samples 
to assess whether the mean rank differs, particularly when the data cannot be assumed to 
be normally distributed (for example, due to small sample size).  Therefore, in this case, 
we direct our focus more towards the p-values of the Wilcoxon rank-sum tests which tells 
us not whether the medians are equal, but rather how much overlap there is between the 
two groups (P. Mitchell, personal communication, February 6, 2013).   
 Finally, the difference of the sum of all immunoglobulin subtypes (IgA + IgE + 
IgM + IgG) between the two subject groups was analyzed using the t-test and Wilcoxon 
rank-sum test. Table 4 and Figure 10 report this data. 
 
 
Table 4:  Sum of Fecal ASCA Immunoglobulin Subtypes (IgA + IgE + IgM + IgG) 
OD450/620 Readings in Patients Crohn Disease - The table highlights the statistical 
differences between the two groups of subjects.  The sample size, mean, standard 
deviation, median, interquartile ranges, as well as the p-values for both statistical tests are 
reported.  *p<.05, active versus inactive Crohn disease. 
 
 
Disease 
Activity 
N Mean±SD 
(OD450/620) 
Pt-test  Median (Q1, Q3) 
(OD450/620) 
PWilcoxon 
   0.04*   0.29 
Inactive Disease 5 0.712±0.574   0.668 (0.359, 0.692)  
Active Disease 13 2.469±2.688   2.040 (0.426, 3.471)  
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Figure 10: Sum of IgA, IgE, IgM, IgG OD450/620 Readings in Inactive and Active 
Crohn Disease - A box and whisker plot reporting the sum of ASCA immunoglobulin 
subtypes in the two groups of subjects is shown.  The difference between the means of 
the two groups is statistically significant when tested parametrically (p-value of t-test = 
0.04), but is not statistically significant when tested non-parametrically (p-value of 
Wilcoxon rank-sum test = 0.29). 
 
 
Effect of Disease Activity on Fecal Lactoferrin  
 In addition to analyzing fecal ASCA levels, the relationship between FLA levels 
and disease activity was explored.  A t-test and Wilcoxon rank-sum test were performed 
to assess the significance of the difference in FLA levels of the two groups.  
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Table 5: Fecal Lactoferrin (IBD-SCAN
TM
) in Patients with Crohn Disease – The 
table highlights the statistical differences between the two groups of subjects.  The 
sample size, mean, standard deviation, median, interquartile ranges, as well as the p-
values for both statistical tests are reported.   
 
Disease 
Activity 
N Mean±SD 
(µg/ml) 
Pt-test  Median (Q1, Q3) 
(µg/ml) 
PWilcoxon 
   0.23   0.20 
Inactive Disease 8 257.19±369.83   104.09 (  17.28, 357.47)  
Active Disease 13 453.73±344.35   616.67 (160.62, 677.88)  
 
 
 
The box and whisker plot pictured in Figure 11 demonstrates the differences in 
median and mean, and also shows the ranges of the data.  The mean FLA levels are lower 
in the inactive disease group, relative to levels measured in patients with active CD.  
However, the difference between the two groups did not reach statistical significance (p-
value of t-test = 0.23; p-value of Wilcoxon rank-sum test = 0.20).   
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Figure 11: Fecal Lactoferrin Levels (IBD-SCAN
TM
) in Inactive and Active Crohn 
Disease - A box and whisker plot reporting FLA levels in the two groups of patients is 
shown.  The plot clearly demonstrates the presence of an outlier. The difference between 
the means of the two groups is not statistically significant when tested parametrically and 
non-parametrically.  However, when the outlier is removed from the inactive group, the 
difference between the means does become statistically significant. 
 
 
The outlier in the inactive disease group contributes disproportionately to the 
mean FLA level of this group.  When this outlier is removed from analysis, the mean 
FLA level measured in patients with inactive disease becomes significantly lower than 
that measured in those with active disease (p-value of t-test = 0.04; p-value of Wilcoxon 
rank-sum test =0.04). 
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Effect of Disease Activity on Albumin 
Parametric and non-parametric tests were performed to determine the significance 
of the differences between the levels of albumin in patients with active and inactive CD.  
Both statistical tests demonstrate that albumin levels are significantly higher in patients 
with inactive disease (p-value of t-test = 0.01; p-value of Wilcoxon rank-sum test = 0.03).  
Table 6 reports the statistical data for the two groups, and figure 12 displays the box and 
whisker plot for this data. 
 
 
Figure 12: Albumin levels in Patients with Inactive and Active Crohn Disease - A 
box and whisker plot reporting albumin levels in the two groups of patients is shown.  
The difference between the means of the two groups is statistically significant when 
tested parametrically and non-parametrically.   
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Table 6: Albumin Levels in Patients with Crohn Disease - The table highlights the 
statistical differences between the two groups of subjects.  The sample size, mean, 
standard deviation, median, interquartile ranges, as well as the p-values for both 
statistical tests are reported.  *p<.05, active versus inactive CD 
 
Disease 
Activity 
N Mean±SD 
(g/dL) 
Pt-test  Median (Q1, Q3) 
(g/dL) 
PWilcoxon 
   0.01*   0.03* 
Inactive Disease 8 4.3±0.3   4.3 (4.1, 4.6)  
Active Disease 12 3.6±0.6   3.8 (3.0, 4.1)  
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DISCUSSION 
 
Pediatric patients with Inflammatory Bowel Disease (IBD) can present with a 
variety of nonspecific gastrointestinal and extra-intestinal symptoms. As a result, 
diagnosis can be delayed in some patients, and this can result in an increased risk for 
growth and pubertal delays, as well as other developmental problems (Kelsen & 
Baldassano, 2008).  There is great need for the development of noninvasive, inexpensive, 
reliable, and objective methods of diagnosing and monitoring this disease.  Fecal 
biomarkers have the potential for meeting all of these requirements, and could greatly 
improve the care and management of patients with IBD.  For example, fecal biomarkers 
such as fecal ASCA or FLA have the potential to: assist clinicians in making an initial 
diagnosis of IBD, help differentiate patients with CD from those with UC, and provide 
information on changes in mucosal disease activity. 
We used an ELISA assay (ASCA-CHEK™) in this study to measure ASCA titers 
in fecal samples from subjects with CD.  Our results confirm that ASCA titers are 
increased in patients with active CD, compared with patients with inactive CD.  This 
result is statistically significant when using both the ASCA-CHEK™ test as well as the 
aggregate ASCA Ig subtypes.  There also appears to be a relationship between specific 
fecal immunoglobulin subtypes and disease activity.  However, the increase in IgA and 
IgM titers in patients with active disease, relative to those measured in patients with 
inactive disease, did not reach statistical significance.  IgE titers were noted to be 
insensitive to changes in disease activity.  In contrast, we found that IgG titers are 
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significantly higher in patients with active disease.  These data suggest that measurement 
of fecal ASCA could be helpful in assessing disease activity in pediatric patients with 
CD.  This may be especially valuable in the context of a disease that is characterized by 
periods of relapse and remission.   
 We also analyzed FLA levels in the two groups using the well-established 
quantitative and qualitative tests (IBD-SCAN™ and IBD-CHEK™).  The difference in 
mean FLA levels was not statistically significant when considering the whole group. 
However when an outlier was removed from the inactive disease group, mean FLA levels 
measured in patients with active disease were significantly higher than those observed in 
patients with inactive CD. These results are consistent with a previous study by 
Pfefferkorn et al. (2010) that similarly demonstrated that FLA is elevated in patients with 
active CD compared to patients with inactive CD.  Studies have shown that FLA is also 
elevated in patients with active ulcerative colitis and as a result, it is thought that FLA 
may not be valuable for discriminating CD versus UC (Abraham & Kane, 2012).   
 Finally, after analyzing albumin levels in the two groups, we found that albumin 
levels are significantly higher in patients with inactive disease than in those with active 
disease.  Hypoalbuminemia is a common clinical finding in patients with active IBD 
(Hendrickson et al., 2002).  As such, our findings support the validity of the disease 
activity status of the two groups.   
 Future studies performed by our group in the Center for Inflammatory Bowel 
Disease at Boston Children’s Hospital will look at the same endpoints in a larger sample 
size.  We will compare fecal ASCA Ig subtype levels with serum ASCA Ig subtype levels 
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and we will include a comparison of the antibody levels in pediatric patients with UC.  
Furthermore, we will assess how these antibody levels change in the same subjects over 
time.  Future studies should evaluate the relationship between ASCA levels and disease 
location, therapy, and need for surgical treatment.  The findings reported in this thesis 
have potential implications for disease subtype stratification.  Larger studies that analyze 
the relationship between fecal ASCA levels and these endpoints could prove valuable for 
improving the clinical management of patients with IBD. 
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